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Background: The direct effect of leucine on insulin signaling and the associated mechanisms have not been established.
Results: Treatment of hepatocytes with leucine facilitates insulin signaling through Gi1 protein.
Conclusion: Leucine facilitates insulin signaling via a Gi protein-dependent pathway.
Significance: This work helps explore how nutrients modulate insulin signaling directly.
In this study, we addressed the direct effect of leucine on insu-
lin signaling. In investigating the associated mechanisms, we
found that leucine itself does not activate the classical Akt- or
ERK1/2 MAP kinase-dependent signaling pathways but can
facilitate the insulin-induced phosphorylations of Akt473 and
ERK1/2 in a time- and dose-dependent manner in cultured
hepatocytes. The leucine-facilitated insulin-induced phosphor-
ylation of Akt at residue 473 was not affected by knocking down
the key component of mTORC1 or -2 complexes but was
blocked by inhibition of c-Src (PP2), PI3K (LY294002), Gi pro-
tein (pertussis toxin or siRNA against Gi1 gene, or -arrestin 2
(siRNA)). Similarly, the leucine-facilitated insulin activation of
ERK1/2 was also blunted by pertussis toxin. We further show
that leucine facilitated the insulin-mediated suppression of glu-
cose production and expression of key gluconeogenic genes in a
Gi1 protein-dependent manner in cultured primary hepato-
cytes. Together, these results show that leucine can directly
facilitate insulin signaling through a Gi protein-dependent
intracellular signaling pathway. This is the first evidence show-
ing that macronutrients like amino acid leucine can facilitate
insulin signaling through G proteins directly.
Increased plasma levels of branched chain amino acids such
as leucine have been shown to be associated with insulin resist-
ance in humans and animals (1–4). Therefore, leucine has been
proposed to be a contributor to the development of insulin
resistance. This assertion is supported by many studies in ani-
mals and cultured cells. For example, infusion of amino acids or
branched chain amino acid leucine can induce insulin resist-
ance (5–9). Exposure of cultured skeletal muscle cells, adi-
pocytes, or hepatocytes to amino acids or leucine can induce
insulin resistance (10–12). In contrast, some studies have
shown that leucine supplementation does not have an effect on
the development of insulin resistance or can even improve insu-
lin sensitivity and prevent the diet-induced obesity (13, 14).
Explanations for these conflicting results are lacking and exact
mechanism by which leucine modulates insulin sensitivity has
not been established.
It has been shown that infusion of leucine can impair glucose
uptake in skeletal muscle and adipose tissue (15) likely through
stimulating insulin secretion (16, 17) because it is known that
excess exposure to insulin can induce insulin resistance (18–
20). Theoretically, leucine is capable of modulating insulin sig-
naling through the mammalian target of rapamycin (mTOR)3
and S6K-mediated serine phosphorylations of IRS1/2 (3, 21). It
is noteworthy that supplementation of leucine can increase
insulin sensitivity in obese animals (13, 14), and the increased
level of branched chain amino acids by knocking out the rate-
limiting enzyme that catabolizes branched chain amino acids is
associated with increased and not decreased insulin sensitivity
(22). The increased insulin sensitivity by branched chain amino
acids can be at least partially explained by decreased food intake
and elevated energy expenditure (13, 14, 22). Similar to leptin,
leucine is capable of activating mTOR that is known to be
involved in inhibition of appetite (23). Moreover, leucine and
isoleucine can actually stimulate glucose uptake in skeletal
muscle (24–26), and leucine can facilitate the insulin-mediated
phosphorylation of Akt in a PI3K-indepndent pathway in adi-
pocytes (27). The direct effect of leucine on hepatic insulin sig-
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naling and the associated mechanism are currently unknown.
In this study, we addressed the direct effect of leucine on insulin
signaling and associated mechanisms.
EXPERIMENTAL PROCEDURES
Reagents—Leucine, human insulin, N6,2-O-dibutyrylad-
enosine 3-5-cyclic monophosphate sodium (cAMP), dexa-
methasome, and Gi protein inhibitor pertussis toxin (PT)
were from Sigma. The c-Src tyrosine kinases inhibitor PP2
and the PI3K inhibitor LY294002 were purchased from Cal-
biochem. The siRNA against Rictor and related scrambled
siRNA were from Sigma. The siRNAs against Gi1, Gi2,
Gi3, Raptor, -arrestin 2 were from IDT (Coralville, IA).
LipofectamineTM RNAi-MAX transfection reagents were
from Invitrogen. Antibodies against total/phospho-Akt (ser-
ine 473), and Rictor were purchased from Cell Signaling
Technology (Danvers, MA). Antibody against Gi1/2/3 was
from Santa Cruz Biotechnology. Antibodies against Gi2 and
Gi3 were from Novus (Littleton, CO) and GeneTex (Irvine,
CA), respectively. Other materials were all obtained com-
mercially and are of analytical quality.
Cell Culture—Hepa1c1c7 andC2C12myocyte cell lines were
obtained from the American Type Culture Collection (ATCC)
and cultured in DMEM supplemented with 10% fetal calf
serum, 2 mM L-glutamine, penicillin (100 units/ml), and strep-
tomycin (100 g/ml) (Invitrogen) at 37 °C in a 5% CO2 humid-
ified incubator at 2 105 cells/ml density. Cells were split every
2 days.
Isolation and Culture of Primary Hepatocytes—Primary
hepatocytes were isolated from unfasted C57BL/6 male mice
(8–10 weeks old, Charles River, NC) as described previously
(28–37). Mice were fed normal diet ad libitum. In brief, under
anesthesia with pentobarbital (intraperitoneal, 50 mg/kg body
weight), isolated liver was perfused with Hanks’ balanced solu-
tion containing 0.5 mM EGTA, 0.004 N NaOH, and 10 mM
HEPES (Invitrogen) at 5 ml/min for 8 min, followed by contin-
uous perfusion with the serum-free Williams’ medium E con-
taining collagenase (Worthington, type II, 50 units/ml) and 10
mM HEPES for 12 min. Hepatocytes were harvested and puri-
fied with Percoll (Sigma). The viability of hepatocytes was
examined with trypan blue exclusion. Only cells with viability
over 95% were used. Hepatocytes were inoculated into colla-
gen-coated plates (5  105 cells/well in six-well plates and
1.25  105 cell per well in 24-well plates) in Williams’ medium
E with 10% fetal bovine serum and were incubated for 24 h
before experimentation.
Measurement of Glucose Production—Glucose production
was assayed as described previously (37). Briefly, hepatocytes
were pretreatedwith 1g/ml PT for 30min orGi1 for 36 h and
then treated with 0.6 mM leucine and/or 10 nM insulin for 30
min in the presence or absence of PT, followed by stimulation
with cAMP/dexamethasome (10 M/50 nM) in glucose-free
DMEM containing 2mM sodium lactate for 2.5 h in the contin-
uous presence or absence of insulin, leucine, and PT. The cul-
ture media were subsequently collected for measuring glucose,
and cells were lysed with the lysis buffer for protein determina-
tion using the Pierce BCAprotein assay kit (Thermo Scientific).
Glucose concentrations were determined with an YSI glucose
analyzer (YSI, Yellow Springs, OH) and normalized to protein
concentrations.
Quantitative Real-time Polymerase Chain Reaction (PCR)—
Total RNAwas extracted from liver samples with TRIzol (Invit-
rogen) and reverse transcribed into cDNA by using a high
FIGURE 1. Leucine facilitates insulin in stimulating phosphorylation of Akt. A, Hepa1c1c7 cells were incubated with increasing amount of leucine in the
presence or absence of insulin (10 nM) for 30 min, followed by evaluations and quantifications of total and phosphorylated Akt by immunoblotting.
B, Hepa1c1c7 cells were treated with insulin (10 nM), leucine (0.6 mM), or both together as noted for a different amount of time, followed by evaluations of total
(T-Akt) and phosphorylated Akt and quantification by immunoblotting. C, Hepa1c1c7 cells were similarly treated as described in B, phosphorylation of Akt at
residue 308 was detected by using immunoblotting. D, C2C12 myocytes were differentiated and then similarly treated as described in B, and phosphorylated
and total Akt were detected by using immunoblotting. Results were presented as the mean  S.E. of four independent experiments, each in duplicate.
Statistical significance is denoted by the presence of different letters above the bars. Bars not sharing a letter are statistically different (p  0.05). **, p  0.01
versus control.
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capacity cDNA archive kit (Applied Biosciences). The cDNAs
were quantified by using a SYBRGreen-based quantitative RT-
PCR kit (Applied Biosciences) and specific oligonucleotide
primers. The following gene-specific primers were used for
mRNA quantification in this study: glucose-6-phosphatase
(mouse), 5-GTGGCTGGAGTCTTGTCAGG-3 (forward)
and 5-ATTGTAGATGCCCCGGATG-3 (reverse); phos-
phoenolpyruvate carboxykinase (mouse), 5-ATGTGTGGGC-
GATGACATT-3 (forward) and 5- AACCCGTTTTCTGGG-
TTGAT-3 (reverse); GAPDH (mouse), 5-AGCTTGTCATC-
AACGGGAAG-3 (forward) and 5-TTTGATGTTAGTGGG-
GTCTCG-3 (reverse).
Immunoblotting—Hepatocytes were lysed in lysis buffer (20
mM Tris-HCl, pH 7.5, 137 mM NaCl, 1 mM Na2EDTA, 1 mM
EGTA, 1% Triton X-100, 2.5 mM sodium pyrophosphate, 1 mM
glycerophosphate, 1 mM Na3VO4, 2 g/ml leupeptin, and 10
g/ml aprotinin), supplemented with 1 mM phenylmethylsul-
fonyl fluoride before use. Lysates (50 g/lane) were resolved in
FIGURE 2. Leucine facilitates insulin in stimulating phosphorylation of ERK1/2 MAP kinase. A, Hepa1c1c7 cells were incubated with increasing amount of
leucine in the presence or absence of insulin (10 nM) for 10 min, followed by evaluations and quantifications of total (T-ERK) and phosphorylated ERK1/2 by
immunoblotting. B, Hepa1c1c7 cells were treated with insulin (10 nM), leucine (0.6 mM), or both together as noted for a different amount of time, followed by
evaluations of total and phosphorylated ERK1/2 and quantification by immunoblotting. Results were presented as the mean  S.E. of four independent
experiments, each in duplicate. Statistical significance is denoted by the presence of different letters above the bars. Bars not sharing a letter are statistically
different (p  0.05).
FIGURE 3. Leucine facilitates insulin signaling through a pathway independent of mTORC2. Hepa1c1c7 hepatocytes were treated with leucine, insulin, or
insulin plus leucine for 30 min, followed by evaluations of phosphorylated mTOR (P-mTOR), total mTOR (T-mTOR), and -actin by immunoblotting and then
quantified. B, Hepa1c1c7 cells were transfected with siRNAs against Rictor or scrambled siRNA for 36 h and were then treated with leucine or insulin alone or
insulin plus leucine for 30 min, followed by evaluations of phosphorylated Akt (at serine 473), total Akt, total Rictor, and -actin by using immunoblotting with
specific antibodies. C, Hepa1c1c7 cell were transfected with siRNAs against Raptor or scrambled (Scr) siRNA for 36 h and were then treated with leucine (0.6 mM)
or insulin (10 nM) alone or insulin plus leucine for 30 min, followed by evaluations of phosphorylated Akt (at serine 473), total Akt, total Raptor, and -actin by
using immunoblotting. Results were presented as the mean  S.E. of four independent experiments, each in duplicate. Bars not sharing a letter are statistically
different (p  0.05).
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4–12% Tris glycine gels (Invitrogen) and transferred to nitro-
cellulose membranes (Bio-Rad). The presence of proteins was
detected by immunoblotting with primary antibodies as indi-
cated and alkaline phosphatase-conjugated secondary antisera.
Fluorescent bands were visualized with a Molecular Imager
VersaDoc MP 4000 System (Bio-Rad) and then quantified by
densitometry analysis using QuantityOne (Bio-Rad).
Gene Silencing with siRNA—The siRNA against Rictor or
scrambled siRNA was introduced into hepa1c1c7 hepatocytes
by reverse transfection with LipofectamineTM RNAiMAX
transfection reagents with the standard approach. In brief, the
siRNA transfection mixture was applied to six-well plates right
before plating hepa1c1c7 hepatocytes in complete DMEM
without antibiotics. The siRNAs against Gi1, Gi2, Gi3, or
scrambled siRNA was introduced into primary mouse hepa-
tocytes by forward transfection with LipofectamineTM
RNAiMAX transfection reagents with the standard approach.
In brief, the siRNA transfection mixture was added to six-well
plates the day after plating primary hepatocytes in complete
Williams’ medium E without antibiotics. After 36 h, cells were
treated with leucine or/and insulin as noted.
Statistical Analysis—Data are presented as mean  S.E. of at
least three independent experiments. Data were analyzed with
one-way analysis of variance, followed by least significant dif-
ference or Dunnett’s. The SPSS software package (version 15.0)
was used for all statistical analyses. Differences at values of p 
0.05 were considered significant.
RESULTS
Leucine Facilitates the Insulin-induced Phosphorylation of
Akt in a Dose- and Time-dependent Manner—To investigate
the direct effect of amino acid leucine on insulin signaling,
hepa1c1c17 hepatocytes were treated with increasing amount
of leucine in the presence or absence of insulin for 30 min,
followed by evaluating phosphorylation of Akt at residue 473.
As shown in Fig. 1A, leucine alone did not stimulate phosphor-
ylation of Akt at residue 473, whereas insulin did. Addition of
leucine enhanced the insulin-mediated phosphorylation of Akt
at residue 473 in a dose-dependent manner, and 0.3 mM of
leucine showed an obvious effect, whereas 0.6 mM of leucine
induced a maximal level of effect. (Note the concentration of
leucine in the culture media used in this study was 157 M; and
the plasma level of leucine in normal subjects ranges between
132.5–176.6 M but between 150.2–234.5 M in obese subjects
(4, 38).) To determine the optimized time point of leucine
effect, hepa1c1c7 cells were treated with 0.6mM of leucine with
FIGURE 4. Leucine facilitates insulin signaling through Gi1 protein. A, Hepa1c1c7 hepatocytes were treated with insulin (10 nM) in the presence of PP2 (100
nM), LY294002 (LY, 10 M), or PT (1 g/ml) for 30 min as noted, followed by evaluations of phosphorylated and total Akt (T-Akt) using immunoblotting and then
quantification. B, Hepa1c1c7 hepatocytes were treated with leucine (0.6 mM) or insulin (10 nM) alone or leucine plus insulin together in the presence of PP2 (100
nM), LY294002 (LY, 10 M), or PT (1 g/ml) for 30 min as noted, followed by evaluations of phosphorylated and total Akt or ERK1/2 using immunoblotting and
then quantification. C, Hepa1c1c7 hepatocytes were first transfected with siRNA against Gi1, Gi2, or Gi3, or scrambled siRNA for 36 h, and then treated with
leucine (0.6 mM) or insulin (10 nM) alone or leucine plus insulin together for 30 min as noted, followed by evaluations of phosphorylated and total Akt, each Gi
isoform protein, and -actin using immunoblotting and then quantification. Results were presented as the mean  S.E. of four independent experiments, each
in duplicate. Statistical significance is denoted by the presence of different letters above the bars. Bars not sharing a letter are statistically different (p  0.05).
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or without insulin for different amount of time (10–60 min),
followed by evaluating phosphorylation ofAkt. As shown in Fig.
1B, leucine facilitated the insulin-mediated phosphorylation of
Akt at residue 473 at 30min clearly, but not at 10, 20, or 60min.
Similarly, leucine facilitated the insulin-induced phosphoryla-
tion of Akt at residue 308 (Fig. 1C). The facilitating effect of
leucine in insulin-mediated Akt phosphorylation was also
observed in differentiatedC2C12myocytes (Fig. 2D). Together,
these results show that leucine can facilitate the insulin-medi-
ated phosphorylation of Akt in a dose- and time-dependent
manner.
Leucine Facilitates the Insulin-induced Phosphorylation of
ERK1/2 in a Dose- and Time-dependent Manner—To investi-
gate the direct effect of amino acid leucine on the other main
branch of insulin signaling, hepa1c1c17 hepatocytes were
treated with increasing amount of leucine in the presence or
absence of insulin for 10min, followed by evaluating phosphor-
ylation of ERK1/2. As shown in Fig. 2A, leucine alone did not
stimulate phosphorylation of ERK1/2, whereas insulin did
stimulate clearly. Addition of 0.3 mM leucine appeared to
enhance the insulin-mediated phosphorylation of ERK1/2
but did not reach a statistical significance until 0.6 mM. To
determine the optimized time point of leucine effect,
hepa1c1c7 cells were treated with 0.6 mM of leucine with or
without insulin for different periods of time (10–60 min),
followed by evaluating phosphorylation of ERK1/2. As
shown in Fig. 2B, leucine facilitated the insulin-mediated
phosphorylation of ERK1/2 at 10 min clearly and faded grad-
ually. Together, these results show that leucine can facilitate
the insulin-mediated phosphorylation of ERK1/2 in a dose-
and time-dependent manner.
The Leucine-facilitated Insulin-induced Phosphorylation of
Akt473 Is mTORC-independent—It has been shown that phos-
phorylation of Akt at residue 473 requiresmTORC2 (39). Thus,
we determined whether mTORC2 activation was required for
the leucine-facilitated and insulin-induced phosphorylation of
Akt at residue 473 by knocking down the core component of
mTORC2, Rictor, with specific siRNA. As shown in Fig. 3A,
leucine alone, insulin alone, or leucine plus insulin all stimu-
lated phosphorylation of mTOR. The siRNA knocked down
Rictor efficiently but had no effect on the leucine- and insulin-
induced phosphorylation of Akt at residue 473 (Fig. 3B). Simi-
larly, knockdown of the core component of mTORC1, Raptor,
FIGURE 5. Leucine facilitation of insulin-mediated phosphorylation of
Akt requires -arrestin 2. Hepa1c1c7 hepatocytes were first transfected
with siRNA against -arrestin 2 or scrambled (Scr) siRNA for 36 h and then
treated with leucine (0.6 mM) or insulin (10 nM) alone or leucine plus insulin
together for 30 min as noted, followed by evaluations of phosphorylated and
total Akt (T-Akt), -arrestin 2, and -actin using immunoblotting and then
quantification. Results were presented as the mean  S.E. of three independ-
ent experiments, each in duplicate. Statistical significance is denoted by the
presence of different letters above the bars. Bars not sharing a letter are sta-
tistically different (p  0.05).
FIGURE 6. Leucine facilitates insulin suppression of hepatic glucose
production through a Gi1 protein-dependent signaling pathway.
Primary hepatocytes were isolated from mouse and cultured as described
under “Experimental Procedures.” A, cells were pretreated with PT (1
g/ml) for 30 min and then treated with leucine or insulin alone or leucine
plus insulin as noted for another 30 min before the stimulation with cAMP
(10 M) and dexamethasome (Dex, 50 nM) in the continuous presence of
leucine (0.6 mM), insulin (10 nM), and PT (1 g/ml) as noted in the serum-
and glucose-free DMEM supplemented with gluconeogenic substrate
sodium lactate (2 mM) for 2.5 h. Glucose production was determined, cal-
culated, and normalized to protein concentrations as described under
“Experimental Procedures.” B, primary hepatocytes were transfected with
siRNA against Gi1, Gi2, Gi3, or a scrambled (Scr) siRNA for 36 h and
treated with leucine, insulin, or leucine plus insulin as indicated for 30 min
before the stimulation with cAMP (10 M) and dexamethasome (Dex, 50
nM) in the continuous presence of leucine (0.6 mM) and insulin (10 nM) as
noted in the serum- and glucose-free DMEM supplemented with gluco-
neogenic substrate sodium lactate (2 mM) for 2.5 h. Glucose production
was determined, calculated, and normalized to protein concentrations as
described under “Experimental Procedures.” Results were presented the
mean  S.E. of three independent experiments, each in triplicate. Statis-
tical significance is denoted by the presence of different letters above the
bars. Bars not sharing a letter are statistically different (p  0.05).
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had no effect on leucine- and insulin-induced phosphorylation
of Akt (Fig. 3C). Together, these results demonstrate that leu-
cine facilitates the insulin-mediated phosphorylation of Akt at
residue 473 through a pathway independent of mTORC
complexes.
Leucine Facilitates Insulin Signaling through a Gi1-depen-
dent Pathway—Because phosphorylation of Akt at residue 473
induced by leucine and insulin was notmediated bymTORC as
shown in Fig. 3, we examined the signaling pathways upstream
of Akt by using inhibition of c-Src, PI3K, or Gi proteins. As
shown in Fig. 4A, phosphorylation of Akt at residue 473
induced by insulin alone was prevented by PI3K inhibitor
LY294002 but not by c-Src inhibitor PP2 or Gi protein inhib-
itor PT. However, phosphorylation of Akt at residue 473 facil-
itated by leucine in the presence of insulin was prevented by
either PI3K inhibitor LY294002 or pertussis toxin (Fig. 4B).
Leucine or insulin alone stimulated phosphorylation of ERK1/2
and leucine plus insulin together further enhanced phosphory-
lation of ERK1/2 (Fig. 4B). Inhibitors against c-Src (PP2), PI3K
(LY294002), or Gi (PT) all appeared to decrease phosphory-
lation of ERK1/2 induced by leucine plus insulin (Fig. 4B). To
determine the isoform of Gi proteins involved in the leucine
effect, we used siRNA to knock down each of the three known
Gi proteins. As shown in Fig. 4C, the siRNA against each iso-
form decreased the level of the target protein significantly, but
only the knockdown of Gi1 prevented the facilitating effect of
leucine in phosphorylation of Akt. Together, these results show
that leucine facilitates insulin signaling through Gi1 protein.
Leucine Facilitation of Insulin-induced Phosphorylation of
Akt Requires -Arrestin 2—To further investigate the mecha-
nism by which leucine facilitates insulin signaling, the involve-
ment of a Gi protein scaffold protein, -arrestin 2, was exam-
ined. It has previously been shown that-arrestin 2 as a scaffold
of Akt and Src plays an important role in insulin-induced Akt
activation (40), but it is unclear whether -arrestin is involved
in the leucine facilitation of insulin signaling.As shown in Fig. 5,
leucine facilitated the insulin-mediated phosphorylation of
Akt. The effects of leucine and insulin on phosphorylation of
Akt were all gone when the -arrestin 2 gene was knocked
down with siRNA. The control siRNA had no effect. Thus,
these results show that leucine facilitation of insulin signaling in
phosphorylation of Akt involves G protein scaffold protein
-arrestin.
Leucine Facilitates Insulin Inhibition of Glucose Production
through a Gi1 Protein-dependent Signaling Pathway—To fur-
ther define the mechanism by which leucine facilitated insulin
signaling, the role for Gi protein in leucine facilitation of insu-
lin-mediated inhibition of glucose production was examined in
cultured primary mouse hepatocytes. As shown in Fig. 6A, glu-
cose productionwas stimulated by cAMP and dexamethasome,
but the stimulation was significantly inhibited by insulin alone,
negligibly reduced by leucine alone, and completely prevented
by the combination of insulin and leucine. The combined inhib-
itory effect of insulin and leucine was also partly blocked by
using either pertussis toxin (Fig. 6A) or Gi1 gene silencing but
not by siRNA against Gi2 or Gi3 (Fig. 6B). Similarly, the leu-
cine-facilitated inhibition of gluconeogenic gene (glucose-6-
FIGURE 7. Leucine facilitates insulin suppression of gluconeogenic gene expression through a Gi protein-dependent signaling pathway. Primary
hepatocytes were isolated from mouse and cultured as described under “Experimental Procedures.” Cells were pretreated with PT (1 g/ml) for 30 min (A and
B) or siRNA against Gi1, Gi2, Gi3, or a scrambled siRNA for 36 h (C and D), then with leucine or insulin alone or leucine plus insulin as noted for another 30 min
before the stimulation with cAMP (10 M) and dexamethasome (Dex, 50 nM) in the continuous presence of leucine (0.6 mM), insulin (10 nM), and PT (1 g/ml)
as noted for 2.5 h, followed by measurements of mRNA levels of glucose-6-phosphatase (G-6-P) and phosphoenolpyruvate carboxykinase (PEPCK) genes using
real time RT-PCR. Results were presented the mean  S.E. of four independent experiments, each in triplicate. Statistical significance is denoted by the presence
of different letters above the bars. Bars not sharing a letter are statistically different (p  0.05).
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phosphatase and phosphoenolpyruvate carboxykinase) expres-
sion was also partially reversed by inhibition of Gi with PT or
siRNA against Gi1 (Fig. 7). Together, these results further sup-
port that leucine facilitates insulin signaling via a Gi1 protein-
dependent signaling pathway.
DISCUSSION
Reports about the regulatory effect of leucine on insulin sen-
sitivity are currently conflicting, and the associated mecha-
nisms have not been fully established. In this study, we investi-
gated the direct effect of leucine on insulin signaling and
associated mechanisms in cultured hepatocytes, and we made
some important findings.
Leucine facilitates insulin signaling through a Gi1 protein-
dependent signaling pathways. Leucine has been shown by
many to impair insulin signaling (10–12). The presumedmech-
anism is associated with activations of mTOR/S6K and conse-
quent serine phosphorylations of IRS1/2 (10, 21). Nevertheless,
elevated plasma levels of branched chain amino acids, including
leucine by knocking out the rate-limiting enzyme of the cata-
bolic pathway of branched chain amino acids, is linked to
increased insulin sensitivity (22). Others have shown that
branched chain amino acids, including leucine and isoleucine,
promote glucose uptake in skeletal muscle cells (24–26). Leu-
cinehasalsobeenshownto facilitate insulin-inducedphosphor-
ylation of Akt via a PI3K-independent manner in adipocytes
(27, 39, 41). It is noteworthy that activation of mTOR may be
able to promote phosphorylation of Akt at residue 473 and con-
sequently facilitate phosphorylation of Akt at residue 308 (39).
The full activation ofAkt requires phosphorylations of both 308
and 473 residues (39). The mTOR-promoted activation of
Akt473 has been shown to bemediated bymTORC2 (39). In this
study, we found that the leucine-facilitated insulin-induced
phosphorylation of Akt at residue 473 was not affected by
knocking down the core components of mTORC1 or 2, Rictor,
or Raptor, suggesting that the leucine facilitated insulin signal-
ing is not mediated by mTOR. Moreover, our results clearly
show that the leucine-facilitated, insulin-induced phosphory-
lation of Akt at residue 473 was c-Src- and PI3K-dependent.
These results together implicate that the effect of leucine on
insulin signaling comes from somewhere upstream of mTOR
and Akt. Interestingly, we observed that leucine facilitation of
insulin-mediated phosphorylation of Akt was prevented by the
Gi protein inhibitor, pertussis toxin, or siRNA against Gi
protein 1 or-arrestin but not by siRNAagainstGi2 orGi3. It
is noteworthy that it has previously been shown that amino
acids such as leucine may be able to trigger intracellular signal-
ing through amino acid transporters, small G proteins, or cur-
rently unidentified membrane receptor(s) (42–44). However,
the involvement of G protein in the leucine-mediated intracel-
lular signaling has not been reported. Furthermore, our results
clearly demonstrate that treatment of cultured hepatocytes
with leucine further increases insulin suppression of glucose
production and expression of key gluconeogenic genes. The
leucine-facilitated insulin suppression of glucose production
and gluconeogenesis was blunted by inhibition of Gi protein.
Finally, our results show that leucine can also facilitate insulin-
induced phosphorylation of ERK1/2. Therefore, we have found
a brandnew signaling pathway bywhich leucine facilitates insu-
lin signaling.
In summary, the findings in this study will not only help
explain how macronutrients such as leucine directly regulate
insulin signaling and metabolism but also help explain why
results are sometimes conflicting among different studies.
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